AI in Drug Discovery and Development Market Expands as Pharmaceutical Companies Invest in Predictive Drug Discovery Platforms

The Global AI in Drug Discovery and Development Market reached US$ 6.24 billion in 2024 and is expected to reach US$ 34.05 billion by 2033, growing at a CAGR of 18.5% during the forecast period 2025-2033. Growth is driven by increasing adoption of artificial intelligence to accelerate drug discovery and reduce development costs. Rising demand for faster identification of drug candidates and improved clinical success rates is supporting market expansion. The growing availability of biomedical data and advancements in machine learning are enhancing research efficiency. Additionally, strategic collaborations between pharmaceutical companies and AI technology providers are accelerating innovation. Expanding investments in precision medicine and next-generation therapeutics are also contributing to strong market growth.

Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?prasad

United States: Recent Developments

✅ In June 2026, Insilico Medicine expanded its AI-driven drug discovery platform with new generative AI models for target identification and lead optimization. The development accelerates early-stage pharmaceutical research. Insilico continues advancing AI-enabled drug development.

✅ In May 2026, Recursion Pharmaceuticals enhanced its AI-powered discovery platform through expanded automated biological data analysis for precision medicine programs. The innovation improves candidate selection efficiency. Recursion continues strengthening AI-based drug discovery.

✅ In April 2026, Schrödinger, Inc. improved its computational drug discovery platform with AI-assisted molecular design for oncology and immunology programs. The development accelerates lead optimization. Schrödinger continues advancing digital drug development.

✅ In April 2026, Pfizer expanded its use of AI-enabled discovery platforms to improve clinical candidate identification and optimize pharmaceutical R&D workflows. The initiative strengthens next-generation drug development capabilities.

Japan: Recent Developments

✅ In June 2026, Takeda Pharmaceutical expanded its AI-driven drug discovery collaborations to accelerate target identification and translational research. The development improves R&D productivity. Takeda continues advancing digital drug discovery.

✅ In May 2026, Astellas Pharma enhanced its AI-based drug discovery capabilities with machine learning models supporting precision medicine programs. The innovation improves therapeutic candidate selection. Astellas continues strengthening AI-enabled research.

✅ In April 2026, Daiichi Sankyo improved its AI-powered discovery workflow by integrating predictive analytics into early-stage pharmaceutical development. The development accelerates pipeline optimization. Daiichi Sankyo continues expanding digital R&D.

✅ In April 2026, Sumitomo Pharma strengthened its AI-assisted drug discovery platform for neurological and psychiatric disease research. The innovation supports faster preclinical development. Sumitomo Pharma continues advancing computational drug discovery.

Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market?prasad

AI in Drug Discovery and Development Market Major Players:

Alphabet Inc.

Alphabet, through Google DeepMind, is a leading innovator in the AI in drug discovery and development market, applying advanced artificial intelligence to accelerate biomedical research and therapeutic discovery. In 2025, the company reported revenue of USD 330.0 billion, driven by digital advertising, cloud computing, and AI services. In the AI in drug discovery and development market, Alphabet plays a major role by leveraging large-scale AI models for protein structure prediction, molecular design, and target identification. Its breakthroughs in AI-driven biology have significantly accelerated early-stage drug discovery and precision medicine research.

Atomwise Inc.

Atomwise is a pioneering AI-driven biotechnology company specializing in structure-based drug discovery. In 2025, the company reported revenue of USD 0.15 billion, driven by pharmaceutical partnerships and AI-powered drug discovery platforms. In the AI in drug discovery and development market, Atomwise plays a key role through its AtomNet® platform, which utilizes deep learning to predict molecular interactions, identify promising drug candid

BenevolentAI

BenevolentAI is a leading AI-enabled drug discovery company that combines machine learning with biomedical data to accelerate therapeutic development. In 2025, the company reported revenue of USD 0.18 billion, driven by strategic collaborations and proprietary drug discovery programs. In the AI in drug discovery and development market, BenevolentAI plays a major role by using knowledge graphs and AI algorithms to identify novel drug targets, optimize candidate selection, and improve the success rate of clinical development.

BioMap

BioMap is a biotechnology company focused on applying foundation AI models to life sciences and drug discovery. In 2025, the company reported revenue of USD 0.12 billion, supported by research collaborations and AI platform development. In the AI in drug discovery and development market, BioMap plays a key role by developing large-scale biological foundation models that accelerate protein engineering, target discovery, and therapeutic design for pharmaceutical and biotechnology companies.

Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/ai-in-drug-discovery-and-development-market?prasad

Segment Covered in the AI in Drug Discovery and Development Market:

By Technology: Machine Learning
Machine learning dominates the AI in drug discovery and development market due to its ability to analyze massive biological datasets, identify novel drug targets, predict molecular interactions, and optimize lead compounds with greater speed and accuracy than traditional methods. Pharmaceutical and biotechnology companies increasingly rely on machine learning algorithms to accelerate drug discovery while reducing development costs and failure rates.
The machine learning segment accounts for approximately 43% of the total market. Based on a global market size assumption of USD 6.24 billion in 2025, this translates to an estimated segment value of USD 2.68 billion. Growth is driven by increasing availability of biomedical data, advances in AI algorithms, and rising collaborations between pharmaceutical companies and AI technology providers.

By Application: Drug Discovery
Drug discovery is the largest application segment as AI is extensively used to identify drug targets, screen compounds, optimize lead candidates, and predict drug efficacy before clinical development. AI significantly reduces the time and cost associated with early-stage drug discovery, making it the primary area of adoption across the pharmaceutical industry.
The drug discovery segment accounts for approximately 61% of the total market. Based on the USD 6.24 billion global market size in 2025, this corresponds to an estimated value of USD 3.81 billion. Growth is driven by increasing R&D investments, growing adoption of generative AI for molecular design, and the need to accelerate the development of therapies for complex diseases.

Market Segmentation
The AI in Drug Discovery and Development Market is segmented by technology into machine learning, deep learning, natural language processing, computer vision, and other AI technologies; and by application into drug discovery, preclinical testing, clinical trials, drug repurposing, and other applications.

Regional Analysis

North America
North America is the leading market due to its strong pharmaceutical ecosystem, advanced AI research capabilities, and significant investments in biotechnology innovation. The region is led by the United States, which hosts many of the world's leading pharmaceutical companies, AI startups, and research institutions focused on drug discovery.
The North American market is estimated at approximately USD 2.81 billion in 2025, accounting for about 45% of the global market. Growth is driven by increasing AI adoption in pharmaceutical R&D, expanding strategic collaborations, and strong venture capital investment in AI-enabled drug development.

Europe
Europe is a major market supported by a robust life sciences sector, growing investment in AI research, and increasing collaboration between pharmaceutical companies and technology providers. Key contributors include United Kingdom, Germany, and France.
The European market is valued at approximately USD 1.75 billion in 2025, representing about 28% of the global market. Growth is driven by expanding AI-driven drug discovery programs, supportive government initiatives, and increasing adoption of computational biology platforms.

Asia Pacific
Asia Pacific is the fastest-growing market due to expanding pharmaceutical manufacturing, increasing AI investments, and growing biomedical research activities. Major markets include China, Japan, India, and South Korea.
The region is valued at approximately USD 1.68 billion in 2025, accounting for about 27% of the global market. Growth is driven by rising healthcare innovation, increasing government support for AI technologies, and expanding partnerships between AI firms and pharmaceutical companies.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?prasad

Data-Driven Research Methodology for the AI in Drug Discovery and Development Market:

Our research process for the AI in Drug Discovery and Development Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.

For More Information@ https://www.datamintelligence.com/research-report/ai-in-drug-discovery-and-development-market

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.

This release was published on openPR.